The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas, India.

WSJ: Daiichi: Ranbaxy Shareholders Hid Information

Under the Application Integrity Policy, the most recent action, the FDA has stopped all scientific review of any new or pending drug approval applications containing data from the Paonta Sahib plant.

CNN: FDA says India plant falsified generic drug data

In its second action in six months against Ranbaxy's Paonta Sahib plant, the FDA invoked its Application Integrity Policy, which is usually invoked over concerns about the integrity of data in drug applications.

CNN: FDA says India plant falsified generic drug data